Skip to main navigation

Targeted Medicine for the Ear

  • Home
  • Careers
  • Contact
Skip to content
  • About
    • Our Story
    • Executive Team
    • Board of Directors
  • Products
    • OTIPRIO®
  • Pipeline
    • Product Candidates
    • OTIVIDEX™
    • OTIPRIO®
    • OTO-313
    • Hearing Loss Programs
    • Clinical Trials
    • Expanded Access Policy
  • Otology
    • Otic Disorders
    • Otonomy Technology
    • Patient Organizations
  • Investors

    Investor Relations

    • OVERVIEW
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Financial Information
      • SEC Filings
      • Annual Reports and Proxies
      • Quarterly Results
    • Stock Information
    • Analyst Coverage
    • Investor FAQs
    • Contact Us

    Shareholder Tools

    • Print Page
    • RSS Feeds
    • Share Page
    • E-mail Alerts
  • News

Investor Relations

  • OVERVIEW
  • Press Releases
  • Events and Presentations
  • Corporate Governance
  • Financial Information
    • SEC Filings
    • Annual Reports and Proxies
    • Quarterly Results
  • Stock Information
  • Analyst Coverage
  • Investor FAQs
  • Contact Us

Shareholder Tools

  • Print Page
  • RSS Feeds
  • Share Page
  • E-mail Alerts
X
  • Share on:
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Reddit
  • Digg
  • Google
  • Delicious
  • StumbleUpon

Annual Reports

Title
  • Add Files
    2018 Proxy 311.3 KB
  • Add Files
    2017 Form 10-K 974.6 KB
  • Add Files
    2017 Proxy 422.7 KB
  • Add Files
    2016 Form 10-K 1.1 MB
  • Add Files
    2016 Proxy 312.5 KB
  • Add Files
    2015 Form 10-K 1.1 MB
  • Add Files
    2014 Form 10-K 1.5 MB
©2019 Otonomy Inc.
  • Terms of Use
  • Privacy